1)van der Bruggen P, et al:A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 254:1643-1647, 1991
2)Dudley ME, et al:Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science 298:850-854, 2002
3)Rosenberg SA, et al:Durable Complete Responses in Heavily Pretreated Patients with Metastatic Melanoma Using T Cell Transfer Immunotherapy. Clin Cancer Res 17:4550-4557, 2011
4)Morgan RA, et al:Cancer regression in patients after transfer of genetically engineered lymphocytes. Science 314:126-129, 2006
5)Rosenberg SA, Yang JC, Restifo NP:Cancer immunotherapy:moving beyond current vaccines. Nat Med 10:909-915, 2004
6)Hoos A, et al:A clinical development paradigm for cancer vaccines and related biologics. J Immunother 30:1-15, 2007
7)Kantoff PW, et al:Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 363:411-422, 2010
8)Wolchok JD, et al:Guidelines for the evaluation of immune therapy activity in solid tumors:immune-related response criteria. Clin Cancer Res 15:7412-7420, 2009
9)Kakimi K, et al:A phase Ⅰ study of vaccination with NY-ESO-1f peptide mixed with Picibanil OK-432 and Montanide ISA-51 in patients with cancers expressing the NY-ESO-1 antigen. Int J Cancer, 2011(Epub ahead of print)
10)Kantoff PW, et al:Overall survival analysis of a phase Ⅱ randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer. J Clin Oncol 28:1099-1105, 2010
11)Hodi FS, et al:Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363:711-723, 2010